Switch theme
Sign up to access all valuation multiples
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
1981
1.8K+
LTM Revenue $676M
LTM EBITDA $129M
$6.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Repligen has a last 12-month revenue (LTM) of $676M and a last 12-month EBITDA of $129M.
In the most recent fiscal year, Repligen achieved revenue of $634M and an EBITDA of $80.3M.
Repligen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Repligen valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $676M | XXX | $634M | XXX | XXX | XXX |
| Gross Profit | $341M | XXX | $275M | XXX | XXX | XXX |
| Gross Margin | 50% | XXX | 43% | XXX | XXX | XXX |
| EBITDA | $129M | XXX | $80.3M | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 13% | XXX | XXX | XXX |
| EBIT | $92.1M | XXX | -$31.9M | XXX | XXX | XXX |
| EBIT Margin | 14% | XXX | -5% | XXX | XXX | XXX |
| Net Profit | $92.6M | XXX | -$25.5M | XXX | XXX | XXX |
| Net Margin | 14% | XXX | -4% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 18, 2025, Repligen's stock price is $116.
Repligen has current market cap of $6.5B, and EV of $6.5B.
See Repligen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.5B | $6.5B | XXX | XXX | XXX | XXX | $1.64 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 18, 2025, Repligen has market cap of $6.5B and EV of $6.5B.
Repligen's trades at 10.3x EV/Revenue multiple, and 81.2x EV/EBITDA.
Equity research analysts estimate Repligen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Repligen has a P/E ratio of 70.6x.
See valuation multiples for Repligen and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.5B | XXX | $6.5B | XXX | XXX | XXX |
| EV (current) | $6.5B | XXX | $6.5B | XXX | XXX | XXX |
| EV/Revenue | 9.6x | XXX | 10.3x | XXX | XXX | XXX |
| EV/EBITDA | 50.7x | XXX | 81.2x | XXX | XXX | XXX |
| EV/EBIT | 70.8x | XXX | -204.2x | XXX | XXX | XXX |
| EV/Gross Profit | 19.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 70.6x | XXX | -256.0x | XXX | XXX | XXX |
| EV/FCF | 69.6x | XXX | 45.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRepligen's last 12 month revenue growth is 13%
Repligen's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Repligen's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Repligen's rule of X is 52% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Repligen and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | 1% | XXX | XXX | XXX |
| Rule of 40 | 34% | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 52% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 48% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Repligen acquired XXX companies to date.
Last acquisition by Repligen was XXXXXXXX, XXXXX XXXXX XXXXXX . Repligen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Repligen founded? | Repligen was founded in 1981. |
| Where is Repligen headquartered? | Repligen is headquartered in United States of America. |
| How many employees does Repligen have? | As of today, Repligen has 1.8K+ employees. |
| Who is the CEO of Repligen? | Repligen's CEO is Mr. Olivier Loeillot. |
| Is Repligen publicy listed? | Yes, Repligen is a public company listed on NAS. |
| What is the stock symbol of Repligen? | Repligen trades under RGEN ticker. |
| When did Repligen go public? | Repligen went public in 1986. |
| Who are competitors of Repligen? | Similar companies to Repligen include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Repligen? | Repligen's current market cap is $6.5B |
| What is the current revenue of Repligen? | Repligen's last 12 months revenue is $676M. |
| What is the current revenue growth of Repligen? | Repligen revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of Repligen? | Current revenue multiple of Repligen is 9.6x. |
| Is Repligen profitable? | Yes, Repligen is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Repligen? | Repligen's last 12 months EBITDA is $129M. |
| What is Repligen's EBITDA margin? | Repligen's last 12 months EBITDA margin is 19%. |
| What is the current EV/EBITDA multiple of Repligen? | Current EBITDA multiple of Repligen is 50.7x. |
| What is the current FCF of Repligen? | Repligen's last 12 months FCF is $93.6M. |
| What is Repligen's FCF margin? | Repligen's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Repligen? | Current FCF multiple of Repligen is 69.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
